STORM Therapeutics is a new biotechnology and drug discovery company, working at the forefront of an emerging field of biology: RNA epigenetics. Advances in the understanding of RNA modifications and their role in disease provide us with novel therapeutic targets and a platform for the discovery and development of first-in-class drugs.
We are looking for ambitious, talented and high-performing individuals who are interested in working in a dynamic start-up environment. We are based at the Babraham Research Campus near Cambridge. The campus is home to some of the world’s most innovative biotechnology companies.
You will be joining a small, strong and culturally diverse team with expertise across industry and academia,that works in close collaboration with Professors Tony Kouzarides and Eric Miska, leading researchers in the field of RNA epigenetics at the Gurdon Institute, University of Cambridge.
STORM Therapeutics offers an industry-competitive salary and benefits package, including performance-related bonus, private medical and life insurance and a contributory pension scheme.
All our current vacancies are listed below. If you do not see a position suitable for you, please check back later, since new opportunities become available regularly.
If you are interested in joining our talented team and working in a stimulating and inspiring environment, please apply for one of the vacancies listed by emailing your CV, together with a covering letter, to: firstname.lastname@example.org
We are now looking to recruit a Scientist or Senior Scientist into our small and dynamic bioinformatics team. This will be a tremendous opportunity to apply and hone your practical skills, integrating and analysing varied biomedical data to direct our existing drug development programmes or identify new targets. Working within the novel field of RNA epigenetics, the role will require an innovative approach and good problem-solving skills.
Due to an expanding drug discovery pipeline, Storm is now looking to recruit a talented, experienced, and enthusiastic pharmacologist with a strong background in small molecule Drug Metabolism and Pharmacokinetics (DMPK).